Project documents | Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578] | Guidance | NICE

Documents

Documents created during the development process.

Draft guidance

Draft guidance
Draft guidance (downloadable version) (PDF 261 KB)

Published:

28 May 2026
Draft guidance (online commenting)
Committee papers (PDF 6.74 MB)

Published:

28 May 2026
Public committee slides (PDF 610 KB)

Published:

28 May 2026
Equality impact assessment (downloadable version) (PDF 125 KB)

Published:

28 May 2026

Committee meetings

Committee meeting: 1

Notes

To appraise the clinical and cost effectiveness of Avapritinib within its marketing authorisation for treating systemic mastocytosis ID6578

Invitation to participate

Final scope (PDF 141 KB)

Published:

23 September 2025
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 460 KB)

Published:

23 September 2025
Equality impact assessment (scoping) (PDF 120 KB)

Published:

23 September 2025
Final stakeholder list (PDF 152 KB)

Published:

23 September 2025

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Provisional stakeholder list post referral (PDF 144 KB)

Published:

05 August 2025
Draft scope post referral (PDF 147 KB)

Published:

05 August 2025